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1 INTRODUCTION 
 
The vitamins essential for living organisms are normally consumed in small amounts 
with the food. These organic materials facilitate the biochemical reactions that produce, among 
others, skin, bone and muscle. Once growth and development are completed, the vitamins 
remain essential nutrients for the healthy maintenance of the cells, tissues and organs; they 
also ensure the efficient use of the chemical energy provided by the food and promote the 
processing of the proteins, carbohydrates and fats required for respiration [1]. 
 
Riboflavin (Fig. 1.), a sparingly water-soluble vitamin that is a component of the co-
enzymes flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) is important in 
the utilization of food and the interconversion of energy. 
riboflavin + ATP                FMN + ADP 
FMN + ATP                 FAD + PP 
 
Riboflavin has no overt pharmacological effects following its oral or parenteral 
administration. FMN and FAD, the physiologically active forms of riboflavin, serve a vital 
metabolic role as coenzymes for a wide variety of respiratory flavoproteins, some of which 
contain metals (e.g. xanthine oxidase) [2]. A deficiency of vitamin B2 is associated with eye 
and skin disorders. 
There are a number of preparations containing riboflavin on the market, e.g. 
effervescent tablets and instant granules. Modern therapy additionally requires a modified 
release dosage form since the riboflavin-containing drugs have poor oral bioavailability due to 
the narrow absorption window in the gastrointestinal tract. 
 
 
2 AIMS 
 
Riboflavin is readily absorbed from the upper gastrointestinal tract by a specific 
transport mechanism involving phosphorylation of the vitamin to FMN. Here and in other 
tissues, riboflavin is converted to FMN by flavokinase, in a reaction that is sensitive to the 
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thyroid hormone status [2]. Altough riboflavin is widely distributed in the body tissues, little 
is stored in the body [3].  
 
Figure 1. Riboflavin 
 
Riboflavin may be absorbed in the duodenum and jejunum, but the extent of absorption at 
these sites is limited because the passage through this region is rapid. The bioavailability of 
riboflavin may be increased by the administration of a gastroretentive or modified release 
dosage form [4]. Techniques are available that permit the production of drugs with poor 
colonic absorption, but better absorption properties in the upper parts of the  gastrontestinal 
tract. These dosage forms may provide excellent results with drugs that act locally in the upper 
regions of the gastrontestinal tracts. 
 
The main goal of the work reported in the thesis was to examine the possibility of improving 
the bioavailability of narrow absorption window drugs through the use of film-coated capsules 
and modified release monolithic matrix tablets. The secondary goal was to identify 
relationships between the rate of release of the drug from capsules or tablets in vitro and the 
corresponding pharmacokinetic profile. 
 
3 LITERATURE SURVEY 
 
3.1 High-shear granulation techniques 
 
Granulation is a size-enlargement process that decreases the specific surface area via 
reduction of the adhesion between the powder particles. Wet and dry granulation are 
distinguished [5-9]. The most frequently used apparatus includes low-/and high-shear 
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granulators, e.g. fluid bed granulators and spray driers [10]. Granulation has two goals: 
manufacture of the final dosage form, or the production of intermediates for tablet compression 
[11]. 
High-shear wet granulation consists in the agglomeration of different particles by liquid 
addition and strong mixing [11-14]. The typical formulation comprises the following phases: 
homogenization of dry powders by use of an impeller; liquid addition; wet massing with the 
liquid feeding system switched off, and finally granule drying [15]. Excipients are regularly 
used, e.g. binders, diluents, disintegrants, stabilizing agents and pigments. Most high-shear 
granulators are fitted with small chopper blades turning at high speeds that break down large 
agglomerates. 
The advantages of high-shear wet granulation advantages are: a shorter process time, 
more dense and less friable granules, and less granulation liquid consumption as compared to 
with other granulators [10].   
 
3.2 Matrix systems 
 
Oral sustained-release technologies may be classified according to different criteria, 
including the type of release (e.g. delayed, slow, prolonged, pulsed, repeat-action, etc.), the 
release machanism (e.g. diffusion, dissolution, etc.) or the type of the technological system. 
They are classified on the basis of their rate-controlling mechanism, e.g. diffusion, 
erosion/chemical reactions, swelling and osmosis. Diffusion-controlled release systems are 
categorized in two types: reservoir systems and monolithic matrix systems. A reservoir system 
utilizes a membrane that serves as the main diffusion barrier, while in a monolithic matrix 
system the active pharmaceutical ingredient (API) is incorporated in a polymer [16-19]. In this 
case the drug dissolution is controlled by diffusion or erosion. The polymer used may be a 
swellable (Fig. 2.) or a non-swellable matrix or an erodable matrix. Natural, hydrophilic 
matrices are used worldwide for oral administration, because they are simple and relatively 
inexpensive modified release formulations. 
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Figure 2. Swellable matrix tablet 
 
The most common naturally-occurring polymers are cellulose, carrageenan, alginate and 
xanthan [20-22].  
Carrageenans are linear polysaccharides, built up from repeating galactose and 3,6- 
anhydroglactose units, either sulfated or non-sulfated.  
 
Figure 3. Major carrageenan fractions 
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The units are joined by alternating alpha 1-3 and beta 1-4 glycosidic linkages. There are 
three main carrageenan forms: lambda, kappa and iota (Fig. 3.), which differ in their chemical 
structures and properties, and therefore in their uses. Lambda-carrageenan does not form gels, 
but yields high-viscosity solutions. Iota-carrageenan forms elastic gels with calcium salts; 
these gels are clear with no bleeding of liquid (no syneresis) and are freeze/thaw-stable. Kappa-
carrageenan furnishes strong, rigid gels with potassium salts, and brittle gels with calcium 
salts. These gels are slightly opaque, but become clear on the addition of sugar and exhibit 
some syneresis [23-26]. Carrageenans are often used in the pharmaceutical industry to 
optimize prolonged-release formulations [27, 28]. 
With the above-mentioned swellable matrices, the rate of disintegration determines the 
drug release profile, and the swelling force is proportional to the rate of disintegration. Study 
of the swelling behaviour of swellable matrices therefore plays an important role in the 
prediction of the drug release profile [22, 29-33]. 
 
3.3 Film coatings 
The oral route is most often used for the administration of drugs. Coated tablets, gelatin 
capsules, granulates and pellets are the major oral dosage forms. Coating is an extremely 
important technique in the formulation of pharmaceutical dosage forms and is a very common 
process in drug manufacturing [34-37]. Coating processes are carried out to provide physical 
and chemical protection for the drugs in the dosage forms, and modification of the drug-release 
characteristics. 
The modern coating techniques began in the 19th century with sugar coating, which 
was principally used to provide a pleasant taste and an attractive appearance for tablets. 
However, the processing time required for the sugar coating is too long, the operator must be 
highly skilled and standardization of the procedure is difficult.  
Film coating has a number of advantages, including time-, material- and work-saving, 
while the film thickness is only 20-100 μm, and the weight gain is ≤150 mg [38]. In general, 
the film coating is applied by using organic solvents or aqueous solutions. Since organic 
solvents tend to be flammable and toxic the applications of organic solvent-based film coating 
are limited and pharmaceutical companies prefer the use of water as solvent [39]. Film-coating 
formulations usually contain the following components:  
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 polymer, 
 plasticizer, 
 pigment, 
 vehicle. 
The film formers in use today are polymers: polymethacrylates, cellulose-based 
polymers, polyvinyl derivativ and other copolymers [40, 41]. The polymer layer is soluble 
(pH-dependent or pH-independent dissolution) or becomes permeable. The research work 
described in the present thesis involved an investigation of the Eudragit NE 30D, a 
polymethacrylate-based (ethyl acrylate–methyl methacrylate) water-insoluble, swelling 
copolymer applied to achieve sustained-release film coating [42-44]. 
A coating process consists in simultaneous spraying, mixing and a drying process. The 
coating process is commonly influenced by the process parameters (e.g. the pan speed, the air 
pressure, the spraying rate, the inlet and outlet air temperatures, the number of spray nozzles, 
the atomization pressure, the coating time, etc.). 
The permeability of the membrane is determined by the thickness of the coating, which 
depends on the above-mentioned parameters and the nature of the polymer layer. 
 
4 EXPERIMENTAL PART 
4.1 SAMPLES I. Production of modified release capsules 
4.1.1 Materials  
Sodium riboflavin 5’-phosphate (BASF AG, Ludwigshafen, Germany) was used as active 
agent (Fig 4.) 1.0 g of sodium riboflavin 5’-phosphate is equivalent to about 0.73 g of 
riboflavin. This salt dissolves in water more easily than riboflavin itself, but it has the same 
absorption and excretion characteristics as those of riboflavin [45]. 
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Figure 4. Sodium riboflavin 5’-phosphate 
 
Cellet 300 (Microcrystalline Cellulose Spheres, Shin-Etsu Chemical Co., Ltd., Tokyo, 
Japan; a gift from Harke Pharma, Mühlheim, Germany) served as core material, and Eudragit 
NE 30D (ethyl acrylate methyl–methacrylate copolymer, Evonik GmbH, Darmstadt, 
Germany) as coating material. The coating dispersion contained Dimeticon E (an antifoaming 
agent, type E1049, a gift from EGIS Pharmaceuticals PLC, Budapest, Hungary) and 
hydrophilic colloidal silicon dioxide (Aerosil 200 (Ph.Eur) and talc (PhEur) as anti-sticking 
agents. Ethanol 96% and purified water were used as solvents. 
 
4.1.2 Methods 
4.1.2.1 Core layering 
The core pellets (Cellet 300) were loaded with a 10% aqueous solution of sodium 
riboflavin 5’-phosphate by a layering technique in a coating pan (Dragex-1, Jorgen Jorgensen 
Maskinfabrik A/S, Copenhagen, Denmark). The rate of rotation speed of the coating pan was 
23 rpm. The nozzle size of the Walther spray gun was 0.8 mm. The atomizing spraying 
pressure was 0.6 bar and the spraying rate was 5 ml/min. The drying temperature was adjusted 
to 30-35 ºC.  
The Cellet layered with sodium riboflavin 5’-phosphate was filled into hard HPMC 
capsules (Capsugel Ltd, Antwerpen Belgium). A Zuma 150/A4 semiautomatic capsule filling 
machine (Zuma Srl, Milan, Italy) was used. 
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4.1.2.2 Capsule coating 
The composition of the coating dispersion was as follows:  
Eudragit NE 30D 75.24 g, Dimeticon E 5.8 g, Aerosil 200 0.44 g, ethanol 96% 18.68 g, 
talc 3.34 g, and purified water 86.74 g. The nozzle size and type were the same as in the 
layering process. The atomizing spraying pressure was 0.8 bar and the spraying rate was 5 
ml/min. The coating pan was rotated at 23 rpm, and the drying temperature was 25-30 ºC. 
The coating dispersion was used in various quantities: 50.0 g (capsule A: dry material 
content: 7.5 g), 100.0 g (capsule B: dry material content: 15.0 g) or 250.0 g (capsule C: dry 
material content: 32.0 g). 
 
4.1.2.3 Tests on coated capsules 
Coating film thickness 
A Mitutoyo screw micrometer was used to determine the thicknesses of the coating film 
on the cap and the corpus of the capsules. The diameter of the capsule was measured with 
0.001 mm accuracy before and after coating. 
Dissolution tests 
The rate of dissolution of the drug was determined by the Münzel half-change method 
[46]. This allows the use of artificial gastric fluid and artificial intestinal fluid of varying pH 
values in the range 1.2-7.5 (Table 1). 
 
Table 1. Variation of pH during the half-change dissolution process 
Interval (h) Gastric fluid/Intestinal fluid pH 
0 – 1 
1 – 2 
2 – 3 
3 – 4 
4 – 5 
5 – 6 
6 – 7 
7 – 8 
100/0 
50/50 
25/75 
12.5/87.5 
6.25/93.75 
3/97 
1/99 
0/100 
1.2 
1.91 
6.24 
6.92 
7.22 
7.39 
7.48 
7.50 
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Dissolution tests were carried out in an Erweka DT 700 dissolution apparatus (Erweka 
GmbH, Heusenstamm, Germany), using a paddle method. The volume of the dissolution 
medium was 900 ml. The test started with gastric fluid (without enzymes), and after each hour 
a sample was taken for concentration determination, and half of the bulk solution was then 
replaced with fresh intestinal fluid. The dissolution temperature was maintained at 37 ± 0.5 °C 
and the rotation rate was set at 100 rpm. Samples (5 ml) were collected automatically from the 
dissolution medium at 1, 2, 3, 4, 5, 6 and 7 h. Three replicates were tested for each capsule 
formulation batch. Absorbance was measured spectrophotometrically (Unicam Heλios Alpha, 
Spectronic Unicam, Cambridge, UK) at λmax = 266 nm. At any time (t), the total quantity of 
drug released from the capsule is defined as given in Table 2. 
Table 2. Amount of drug released as a function of time  
t 
(h) 
Concentration of solution 
(%) 
Total drug amount released (At) 
(%) 
 
1 
2 
3 
 
Q1 
3
2
Q
Q1 
 
3
22
Q
QQ 21 
 
 
A1 
A2 
A3 
n 
n
1/-/n21 Q
Q
....
QQ

222
 
An 
 
4.1.2.4 Statistical evaluation 
Model-independent evaluation 
The dissolution efficiency (DE) can be calculated via the following expression: 
100
)(
100
0 

tm
dttm
DE
t
 (1) 
where m(t) is the amount of API dissolved at time t, and 100m  is the amount of API dissolved 
at 100% dissolution.  
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Model-dependent evaluation of dissolution curves 
Depending on the shape of the dissolution curve, various mathematical models can be 
used to describe the dissolution process (first-order, Higuchi, Hixson–Crowell, Hopfenberg, 
Korsmeyer–Peppas, Rosin–Rammler–Sperling–Benett–Weillbull (RRSBW) (modified 
Weibull), etc.) [47]. The RRSBW model is generally utilized to describe the dissolution profile 
in the event of a sigmoid shape. Another model that can be used in this case is the Chapman–
Richards model [48].  
The coefficient of determination (R2) is frequently used as criterion to assess the best 
model equation. In this study we applied RRSBW distribution and the Chapman–Richards 
growth function to fit the dissolution profiles.  
 
RRSBW model 
RRSBW distribution is commonly used as the mathematical model in dissolution studies 
[49, 50]. This distribution is generally described by the following empirical equation: 
)1()(
)(
a
Tt
eMtM


   (2) 
where M(t) is the amount of API dissolved as a function of time t, M   is the maximum amount 
of API dissolved, T is the lag time, a is a scale parameter that describes the time dependence, 
and β describes the shape of the curve. 
For β = 1, the shape of the curve corresponds exactly to the shape of an exponential 
profile with constant k = 1/a. This implies first-order kinetics in the dissolution process: 
)1()( )( TtkeMtM    (3) 
For β = 0, the equation is  
)1()(
1
aeMtM

   (4) 
For β < 1, relatively rapid dissolution is observed at the beginning of the process, 
followed by a slower process.  
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For   aTt   , the equation is  
632.011
)( 1  


ee
M
tM
a
a
 (5) 
where a = t63.2%  is a characteristic dissolution time. 
 
Chapman–Richards model 
The Chapman–Richards method involves a 3-parameter sigmoid growth function based 
on the Bernoulli differential equation. This differential equation is used to describe the growth 
of an arbitrary quantity as the difference between its constructive growth and destructive 
growth [51]: 
MM
dt
dM
    (6) 
where M is the quantity, M is the constructive part and M is the destructive part. The 
general solution of this differential equation is the 3-parameter Chapman–Richards function: 
)1()( kteMtM    (7) 
where M , k and   are the regression parameters to be estimated.   
The dissolution profiles were fitted with Eq. 7, where M(t) is the amount of API 
dissolved as a function of time, M is the total amount of the API, k  is the dissolution rate 
and   describes the shape of the curve, which refers to the lag time of the dissolution. 
As in the RRSBW model, β = 1 implies first-order kinetics.  
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4.1.3 Results 
 
Coating film thickness 
The film thickness the and uniformity of the coating play an important role in the dissolution. 
It was therefore important to determine the film thickness. 
The measurement data are summarized in Table 3. 
 
Table 3. Film thickness on the capsule surface 
Capsule Film thickness (m) 
Cup              Corpus 
A 161  12 182  5 
B 200  20 240  36 
C 227  26 269  36 
 
The film thickness is seen to increase with increase of the coating dispersion, but the data also 
reveal a difference in the thickness of the films on the cup and the corpus of the coated 
capsules. The latter is primarily due to the shape of the capsules: there is always some 
difference (~30-40 m) in the diameters of the cup and the corpus. The difference in the film 
thickness is not more than in the case of the uncoated capsule. This suggests that the coated 
dispersion spreads on the surface of the capsules during coating, and forms a uniform coating 
film on the surface of the capsules. 
Dissolution tests 
In the first step, we tested the rate of dissolution rate of riboflavin from uncoated capsules in 
artificial gastric fluid for comparison with the coated capsules. The results showed that the 
total riboflavin (100%) dissolved during 60 min.  
The dissolution tests (by half change method) on the coated capsules clearly demonstrated the 
influence of the film thickness on the release of the drug (Fig. 5.).  
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Figure 5. Dissolution of riboflavin from coated capsules 
Table 4. Parameters of dissolution curves 
Capsule RRSBW model Chapman–Richards model 
   a R2 
M    k R
2 
A 1.3602 1.3186 0.9171 69.6771 16.8461 1.66817 0.9991 
B 1.6813 2.4113 0.9228 42.2965 5.2131 0.8363 0.9970 
 
The dissolution profile exhibited a sigmoid shape in the cases of capsules A and B. These are 
typical dissolution curves of a delayed-release dosage form. However, capsule A is to be 
preferred in view of the present aim, because much of the API (~70%) was released at pH ≈ 7.  
The independent statistical evaluation of the results demonstrated that the efficiency of the 
mechanism of dissolution (DE) was highest in the case of capsule A.  
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Table 5. Results of the model-independent evaluations 
Capsule DE (%) 
A 54.14 
B 28.47 
C 4.2 
 
Various mathematical models were tested to describe the dissolution process (see above), and 
the RRSBW and Chapman–Richards model proved best. The results with these are presented 
in Table 4.  
The R2 data revealed that the dissolution curves for capsules A and B are well described by the 
Chapman–Richards equation. 
The curve for capsule C was fitted by linear fitting (R 2= 0.9949), but the corresponding DE 
was not high enough, and hence it was not considered further. 
The data in Table 5 demonstrate that the DE of capsule A was best, but the amount of API 
dissolved was only ≈70%. It is also evident that the coating film thickness influences the 
degree of dissolution of the drug. The question arises as to how the bioavailability of riboflavin 
from the capsules can be enhanced. What is the best film thickness for total release to be 
attained in the small intestine during 2-5 h?  
To answer this question, we created a theoretical model based on the Chapman–Richards 
method with respect to the fitting results. In this model, 95-100% of the API is released 
between 2 and 5 h. On the basis of this theoretical model and the measurement results, we 
calculated the optimum thickness of the coating via the following formula: 
BA
Am
ABAopt
ss
ss
dddd


 )(
   (8) 
where dopt is the optimum thickness, dA, and ,dB  are the thicknesses of the films on capsule A 
and capsule B, sm is the slope of the model dissolution profile, and sA and sB are the slopes of 
the dissolution curves for capsule A and capsule B, respectively.  
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In this case, the predicted optimum film thickness on the corpus which ensures the required 
dissolution is 112.1 m (Fig. 6.). 
 
 
Figure 6. Predicted dissolution profile at a film thickness of 112.1 m on the corpus 
 
4.1.4 Discussion 
 
In this work, a new solid dosage form was developed through the layering of aqueous sodium 
riboflavin 5’-phosphate solution on the surface of microcrystalline pellets (Cellet 300) as core 
material, which were then filled into capsules. The hard capsules were coated with Eudragit 
NE coating material in different thicknesses. Naturally, further pharmacokinetic testing is 
necessary to confirm the appropriate bioavailability. Statistical analysis of the dissolution 
curves indicated that the best products were described by the Chapman–Richards equation. 
The results were utilized to create a theoretical model suitable for prediction of the optimum.  
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4.2 SAMPLES II. Development of matrix tablets 
4.2.1 Materials 
 
Sodium riboflavin 5’-phosphate (BASF AG, Ludwigshafen, Germany) was used as API, 
Gelcarin GP 379 NF (iota-carrageenan) (FMC BioPolymer, Philadelphia, USA) as 
swellable matrix material, microcrystalline cellulose (MCC) (Vivapur® 102) 
(Rettenmaier&Söhne GmbH, Rosenberg, Germany) as non-swellable matrix-forming 
wicking material, and lactose (PhEur) as a filling excipient. 
4.2.2 Methods 
4.2.2.1 Preparation of granules 
 
The homogenization and wetting of the powder mixture were performed in a high-shear mixer 
(ProCepT 4M8 granulator, ProCepT nv, Zelzate, Belgium; Fig 7.).  
 
 
Figure 7. ProCepT 4M8 granulator 
 
The ratios of the powder components were varied according to a 32 factorial design, as in Table 
6. 
Table 6. Compositions of powder mixtures 
Gran 
code 
Iota-
carrageenan 
(%) 
MCC 
(%) 
α-lactose 
monohydrate 
(%) 
MCC/(MCC 
+lactose) 
ratio (%) 
Gran1 30 45 25 64.5 
Gran2 30 55 15 78.6 
Gran3 30 35 35 50 
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Homogenization parameters: 
Impeller speed: 1000 rpm 
Chopper speed: 0 rpm 
Homogenization time: 5 min 
 
Kneading parameters: 
Impeller speed: 1000 rpm 
Chopper speed: 5000 rpm 
Dosing speed: 10 ml/min 
Amount of API solution: 120 ml (in three portions) 
 
The wet granules obtained were sieved through a sieve with 1.2 mm wire distance and were 
dried at 22  2 ºC/65  5% relative humidity. 
 
4.2.2.2 Tableting 
 
The dry granules were mixed with 2% of magnesium stearate in a Turbula mixer at 50 rpm, 
for 2 min. The resulting granules were compressed into tablets at 5, 10 or 15 kN with a Korsch 
EK0 instrumented eccentric tablet machine (Emil Korsch Maschinenfabrik, Berlin, Germany). 
The compression tools were slightly concave punches 9 mm in diameter, the pressure force 
was calibrated with a Wazau HM-HN-30kN-D cell (Kaliber Ltd., Budapest, Hungary), and the 
compression was carried out electrically at 36 rpm, at 24 C air temperature and 45% relative 
air humidity. The average mass of the tablets was 0.200 ± 0.01 g. 500 tablets were compressed 
at each compression force for each sample (when possible). Lots with relative standard 
deviations not exceeding 5% were accepted.  
Model tablets for swelling investigations were also prepared with the above-mentioned Korsch 
EK0 eccentric tableting machine, but these tablets contained only the matrix former polymer 
(iota-carrageenan). The applied compression forces were again 5, 10 and 15 kN. 
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4.2.3 Physicochemical evaluation of tablets 
 
The average and individual masses were measured with an analytical balance (Sartorius AG, 
Göttingen, Germany). The breaking strength (Heberlein, Flisa, Le Locle, Switzerland), 
friability (Erweka GmbH, Heusenstamm, Germany) and geometry of the tablets, including 
thickness and diameter (Mitutoyo screw micrometer, accuracy 0.001 mm, Mitutoyo Co. 
Kawasaki, Japan), were determined. 20 tablets were tested in every case. 
 
4.2.4 Dissolution study and release modelling 
 
Dissolution tests were carried out in an Erweka DT 700 dissolution apparatus (Erweka GmbH, 
Heusenstamm, Germany), using the paddle method (Dissolution test for solid dosage forms – 
Apparatus 2 (paddle method) [52].  
The dissolution was tested in gastric fluid (pH = 1.2) and phosphate buffer (pH = 4.5). At the 
beginning of the process, the dissolution medium was 900 ml of gastric juice (adjusted 
according to the Ph. Eur.). The dissolution temperature was maintained at 37 ± 0.5 °C and the 
rotation rate was set at 100 rpm. Samples (2 ml) were automatically collected from the 
dissolution medium at 30, 60, 90 and 120 min. The dissolution medium was then changed to 
phosphate buffer under the former conditions and samples were again taken at 30, 60, 90, 120, 
150 and 180 min. The total potential dissolution time was therefore 300 min (5 h). Three 
replicates were tested for each tablet formulation batch. Absorbance was measured 
spectrophotometrically (Unicam Heλios Alpha, Spectronic Unicam, Cambridge, UK) at λmax 
= 266 nm. 
The dissolution data were calculated by statistical analysis and the release profiles were fitted 
with different models. 
 
4.2.5 Factorial design 
 
To reveal the relationships between composition, process parameters and tablet properties, the 
experiments were performed according to a 32 full factorial design (Statistica for Windows). 
The independent factors were the MCC/(MCC + lactose) ratio in the composition and the 
applied compression force. The optimization parameters were the amount of API dissolved 
after 5 h, and the friability and breaking hardness of the tablets. 
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4.2.6 Measurement of swelling 
 
Swelling force was measured with equipment developed in our laboratory (see below). Tablets 
were prepared at different pressures (see below) and their swelling was tested in hydrochloric 
acid of pH 1.2 and in phosphate buffer of pH 4.5. The temperature applied was 37 ºC and the 
duration of measurements was 30 min. Five parallels were measured. 
The measurement was performed with a Sartorius microbalance with electronic compensation, 
built into the equipment with the DAQ hardware. The built-in DAQ unit is based on a 
PIC16F871-I/P microcontroller. The Sartorius balance and the temperature sensor were 
connected to ADC channel 0 and channel 1, respectively. The equipment was linked to a PC 
via an RS232 cable as shown in Fig. 8. 
The tablet-holder was a copper cylinder 10 mm in diameter with slits in the side, into which a 
copper punch with the same diameter was fitted. The tablet was placed in the holder, the 
equipment heated the aqueous solution to the desired temperature, the liquid was injected and 
measurements were started.  
The aqueous solution penetrated into the tablet through the slits. The force that built up inside 
the comprimate as it absorbed the liquid was transmitted vertically and was detected by the 
built-in Sartorius balance. During the measurement, the embedded software used the timer 
interrupt for the DAQ from the ADC channels [53]. 
 
 
Figure 8. Experimental set-up of the swelling force meter [54] 
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Software was developed for data acquisition, evaluation and demonstration of the swelling 
process. The monitor displayed the swelling force vs. time curve with the important parameters 
(the swelling force and the characteristic swelling time (t63.2%)). An Analysis menu facilitated 
fitting of the swelling curve. 
4.2.7 Results and discussion 
4.2.7.1 Granulation 
 
In the high-shear granulator used, it was possible not only to set the important working 
parameters, but also to follow the process and measure the changes in temperature and impeller 
torque. The latter parameter is very informative because it shows the optimum end- point of 
the suitable consistency of the wet mass. Many publications have dealt with the importance of 
end-point detection and the influence on this of the composition of the granules [15, 55, 56]. 
Our experiments revealed (Fig. 9.) that the MCC/(MCC + lactose) ratio (in the range used) did 
not significantly influence the temperature increase (about 20 ºC). Likewise, there were not 
great differences in impeller torque, but there was a tendency for the end-point to increase to 
a small degree with increase of the lactose content. The impeller torque was 23% at the 
MCC/(MCC + lactose) ratio of 78.6% (Gran2); 26% at the MCC/(MCC + lactose) ratio of 
64.5%  (Gran1), and 31% at the MCC/(MCC+lactose) ratio of  50% (Gran3). 
 
 
Figure 9. Granulation process of Gran2 sample 
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4.2.7.2 Tableting 
 
The redispersed dry granules (moisture content: 5.00  0.5%) were mixed with magnesium 
stearate and compressed. The physicochemical parameters of the tablets are presented in 
Table 7. 
 
Table 7. Physicochemical parameters of tablets 
Samples Compression
force 
(kN) 
Mass 
 
(g) 
Breaking 
hardness 
(N) 
Friability 
 
(%) 
Diameter 
 
(mm) 
Height 
 
(mm) 
Ribotab1 
(ratio 64.5) 
5 
10 
15 
0.192 
0.211 
0.204 
48.35 
50.90 
54.80 
0.50 
0.48 
0.43 
8.994 
8.999 
8.993 
2.597 
2.526 
2.444 
Ribotab2 
(ratio 78.6) 
5 
10 
15 
0.195 
0.197 
0.195 
37.50 
37.10 
37.60 
1.54 
1.21 
1.07 
8.911 
8.932 
8.940 
2.409 
2.445 
2.421 
Ribotab3 
(ratio 50) 
5 
10 
15 
0.200 
0.210 
0.200 
38.63 
57.95 
59.40 
0.33 
0.36 
0.14 
9.058 
9.036 
9.033 
2.508 
2.507 
2.383 
 
 
It can be seen from the data that the accuracy of the mass was good; this means that the 
flowability of the granules and the filling of the die cavity were uniform. The mechanical 
parameters (breaking hardness and friability) demonstrate the differences between the 
samples.  
The results were evaluated according to the factorial design, the factors are described in section 
4.2.5 . The design matrix and the corresponding results are to be seen in Table 8. 
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Table 8. Design of experiments 
MCC/(MCC + lactose) 
ratio (%) 
Compression 
force (kN) 
Breaking 
hardness (N) 
Friability (%) Amount of drug 
dissolved after  
5 h (%) 
50.0 
50.0 
50.0 
5.0 
10.0 
15.0 
38.63 
57.95 
59.40 
0.33 
0.36 
0.13 
100 
100 
82 
64.5 
64.5 
64.5 
5.0 
10.0 
15.0 
48.35 
50.90 
54.80 
0.50 
0.48 
0.42 
65 
63 
51 
78.6 
78.6 
78.6 
5.0 
10.0 
15.0 
37.50 
37.10 
37.60 
1.54 
1.22 
1.07 
71 
84 
82 
 
 
The mechanical properties of the tablets seemed more robust than the dissolution data. (The 
dissolution curves are displayed below.) Neither the composition nor the compression force 
influenced this parameter significantly (Eq. 9); only the linear component of the MCC/(MCC 
+ lactose) ratio proved to be of  minor significance when the non-linear interactions were not 
taken into account, but this resulted in a decreased goodness of fit (R2 = 0.8266 vs. 0.9393). 
 
y = 46.91 - 7.30x1 + 3.33x1
2 + 4.55x2 + 1.30x2
2 - 5.17x1x2 - 2.35x1x2
2 - 1.23x1
2x2
2   (9) 
 
The decreasing value of the breaking hardness (Fig. 10.) and the corresponding increase in 
friability (Fig. 11.) may be due to the resistance of the granules against compression at high 
MCC content.  
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Figure 10.  Response surface for the breaking hardness of the tablets 
 
The results suggest that MCC loses its deformability during granulation, which results in a 
decreased binding capacity and a decreased mechanical strength of the tablets. Nevertheless, 
the mechanical problems are connected more with the abrasion than with the breaking of the 
tablets, as indicated by the higher sensitivity of the friability to the composition of the tablets 
(Eq. 10).  
 
y = 0.67 + 0.50x1 - 0.15x12 - 0.12x2 + 0.008x2
2 - 0.07x1x2    (10) 
 
The significant factors are indicated with bold-faced type.  
The MCC/(MCC + lactose) ratio significantly influenced the friability both linearly and non-
linearly. Unfortunately, the consideration of the quadratic interactions resulted in 
overdetermination of the model, and these effects were therefore neglected during the analysis. 
 
The data in Table 6 demonstrate that in the case of Ribotab1 [MCC/(MCC + lactose) ratio   
64.5%] the compression force did not influence the hardness of the tablets or the geometrical 
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parameters. The Ribotab2 tablets exhibited a very a small breaking hardness, which was 
independent of the compression force. These tablets contained the smallest proportion of 
lactose (Gran2). With the MCC particles, the carrageenan formed a monolithic matrix with 
elastic behavior, which was not disturbed by the lactose particles. This was explained by the 
friability values, which revealed a higher elastic recovery in the tablets after compression. The 
compensatory behaviour of the MCC particles was not sufficient. Ribotab3 was prepared with 
much more lactose (Gran1). In this case the tablets produced at 5 kN exhibited a small breaking 
hardness, which increased with increasing compression force, especially at 10 kN. Further 
increase of the compression force caused only a very small increase in hardness. The friability 
values indicated stronger binding in the texture of the tablets in the elastic recovery phase.  
 
The results of the statistical evaluation revealed that even when the non-significant interactions 
between the factors were taken into account, the goodness of the fitted model increased 
significantly. In the case of the API dissolution, the adjusted R2 was 0.7712 with no 
interactions, 0.9490 with linear interactions, and 0.9972 with the application of the quadratic 
interactions too. It can be concluded that the API dissolution is mostly affected by the 
MCC/(MCC + lactose) ratio, and a strong non-linear relation can be observed between these 
two parameters (Fig. 12.). The compression force applied had a non-significant effect on this 
parameter, but it strongly interacted with the compositional parameter (Eq. 11).  
 
y = 77.56 - 7.50x1-13.42x12-3.50x2 + 3.58x2
2 + 7.25x1x2 - 2.63x1
2x2 - 0.81x1
2x2
2  (11) 
 
The significant values are highlighted in bold-type format. The highest values of dissolution 
were observed at high lactose content, which can be explained by the increasing porosity of 
the matrix due to the dissolution of the lactose. Nevertheless, the higher dissolution rate at low 
lactose proportions may be due to the weak effect of the MCC which results in a higher rate 
of water penetration into the matrix and forced dissolution of the drug from the internal pores 
of the system.  
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Figure 11. Response surface of the friability 
 
 
Figure 12. Response surface of drug dissolution 
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The dissolution curves of the tablets are displayed in Figs 13-15. It can be observed that the 
curves frequently display a break-point. 
In the case of Fig. 13. (Ribotab1), a break-point is not seen in the curve at 5 kN, but with 
increase of the compression force the break-point becomes clearer. This is in accordance with 
the hardness values of these tablets. In the tablets compressed at 5 kN, the binding can break 
more easily in the gastric juice; the texture of the tablets is more porous. The swelling of the 
macromolecular particles come off streamline; and at the change of the dissolution medium, 
the gastric juice can wash out readily from the matrix. In the case of a compact matrix system, 
it is more difficult for the phosphate buffer to pass into the interior of the tablet.  
Ribotab2 (Fig. 14.) contained the lowest proportion of lactose. At 5 kN, where the matrix 
formed was more porous, the macromolecular particles could swell readily in the gastric juice 
and the API could dissolve. However the swelling later resulted in a gel form and, after the 
change of the dissolution medium, the phosphate buffer could not pass easily into the swollen 
particles; at first, a saturated section occurred in the dissolution profile. The degree of swelling 
of the carrageenan particles hindered the complete release of the API. In this case, the 10 kN 
compression force was best for the preparation of the tablets, because the texture of the tablets 
and the swellability were in equilibration. The release profile showed a uniform increase up to 
80%. The tablets compressed at 15 kN also showed that the particles of the macromolecules 
did not swell to such a high degree and the dissolution rate was practically the same as for the 
former tablets.  
Figure 15 best demonstrated the role of lactose during the dissolution process. The Ribotab3 
tablets contained lactose in highest proportion in the matrix system. The particles of lactose 
could disperse to a high degree between the macromolecular particles. It can be seen from 
Table 7 that the mechanical hardness of these tablets was the weakest; it is well known that 
lactose is a brittle material and is not able to form hard binding during loading [57]. The 
dissolution process of the tablets compressed at 5 kN is not depicted here as the deviation was 
too high. Only the dissolution profiles, of the 10 and 15 kN tablets are illustrated. Lactose, a 
well-soluble excipient, which can be incorporated between the macromolecular particles, 
promotes the release of the API. The total amount of the API was dissolved from the tablets 
compressed.at 10 kN. Further increase of the compression force would not have been 
advantageous, because the more compact texture prevented the total dissolution of the API 
during 5 h. 
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The dissolution data were subjected to statistical analysis. The Korsmeyer–Peppas model (Eq. 
12) proved to characterize the total dissolution profile best: 
nt kt
m
m


 (12) 
where mt/m is the fraction of the API released at time t, k is the rate constant and n is the 
release exponent. 
The R2 values revealed rather strong correlations (Table 9.), but because of the break-points in 
the dissolution profiles, we took the dissolution data in two groups and fitted all the sections 
according to the Korsmeyer–Peppas and the linear model. The first section was the period 0-
120 min and the other 150-300 min. The results are presented in Tables 10 and 11. 
It can be seen from the data in Table 10 that the correlation is strong, especially in the first 
section of the dissolution profile. 
The fitting with the linear model was also examined: 
bat
m
mt 

 (13) 
where mt/m is the fraction of the API released at time t, a is the slope and b is the intersection. 
 
Figure 13.  Dissolution curves for Ribotab1 samples 
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Figure 14. Dissolution curves for Ribotab2 samples 
 
 
Figure 15. Dissolution curves for Ribotab3 samples 
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Table 9. Fitting results of total dissolution profile 
Samples k n R2 
Ribotab1-5kN 
Ribotab1-10kN 
Ribotab1-15kN 
0.9403 
1.0956 
1.2816 
0.7525 
0.7149 
0.6483 
0.9924 
0.9916 
0.9866 
Ribotab2-5kN 
Ribotab2-10kN 
Ribotab2-15kN 
2.6359 
1.7948 
1.0872 
0.5789 
0.6788 
0.7700 
0.9860 
0.9920 
0.9777 
Ribotab3-10kN 
Ribotab3-15kN 
1.2199 
0.7881 
0.7808 
0.8148 
0.9888 
0.9930 
The tablets produced at 5 kN exhibited a low breaking hardness, and the dissolution process 
was not depicted here as the deviation was too high; these samples were omitted from the 
further experiments. 
 
 
Table 10. Fitting results of each section of dissolution according to the Korsmeyer–Peppas 
model 
Samples 0–120 min 150–300 min 
k n R2 k n R2 
Ribotab1-5kN 
Ribotab1-10kN 
Ribotab1-15kN 
0.5277 
0.3537 
0.3052 
0.8734 
0.9690 
0.9782 
0.9986 
0.9972 
0.9982 
1.8832 
1.4535 
1.2273 
0.6262 
0.6627 
0.6547 
0.9637 
0.9705 
0.9914 
Ribotab2-5kN 
Ribotab2-10kN 
Ribotab2-15kN 
0.7368 
0.6548 
0.3487 
0.8723 
0.9001 
1.0011 
0.9971 
0.9996 
0.9991 
2.9937 
3.7644 
5.5042 
0.5542 
0.5434 
0.4751 
0.9870 
0.9944 
0.9987 
Ribotab3-10kN 
Ribotab3-15kN 
0.8557 
0.4046 
0.8426 
0.9562 
0.9971 
0.9782 
3.7482 
1.4330 
0.5771 
0.7060 
0.9947 
0.9929 
 
 
 
33 
 
 
Table 11. Fitting results of each section of dissolution according to the linear model 
Samples 0–120 min 150–300 min 
a b R2 a b R2 
Ribotab1-5kN 
Ribotab1-10kN 
Ribotab1-15kN 
0.2845 
0.3025 
0.2736 
1.0700 
0.4147 
0.2423 
0.9956 
0.9972 
0.9982 
0.1574 
0.1562 
0.1246 
20.1773 
17.1817 
14.2783 
0.9545 
0.9685 
0.9929 
Ribotab2-5kN 
Ribotab2-10kN 
Ribotab2-15kN 
0.3946 
0.4027 
0.3494 
1.5450 
1.1415 
0.1023 
0.9943 
0.9977 
0.9991 
0.1497 
0.1742 
0.1543 
26.1577 
31.7570 
36.9603 
0.9923 
0.9961 
0.9964 
Ribotab3-10kN 
Ribotab3-15kN 
0.3968 
0.3300 
1.8949 
0.1267 
0.9925 
0.9776 
0.2213 
0.2065 
35.0401 
18.7888 
0.9890 
0.9959 
 
The results show, that both of the sections can be fitted by the linear model too. However the 
results with the Korsmeyer–Peppas model indicated that the matrix model fitting was better in 
most cases. 
In earlier work, in which the swelling properties and swelling forces of different disintegrants 
were tested, it was concluded that in the case of disintegrating tablets the swelling curve can 
be fitted by the RRSBW equation (Eq. 2), and the swelling process can be characterized by 
the RRSBW model [53, 54].  
In the present work, we studied the swelling properties of matrix tablets 
Gelcarin GP 379, a swellable carrageenan, was used in the present experiment, and the tablets 
did not contain other excipients. The measured swelling force was therefore attributable only 
to the swelling of iota-carrageenan. The experiments were carried out at pH 1.2 and pH 4.5, 
both of which are to be found in the gastrointestinal tract. The results are shown in Table 12.  
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Table 12. Swelling of iota-carrageenan tablets 
Duration of experiments: 30 min, temperature: 37  1 ºC 
Compression force 
(kN) 
pH Swelling force  
(N) 
Swelling time 
(min) 
5 1.2 3.006 
SD = 0.098 
28.54 
SD = 3.26 
4.5 2.952 
SD = 0.388 
24.8 
SD =  3.93 
10 1.2 2.106 
SD =  0.885 
28.16 
SD =  2.05 
4.5 3.19 
SD =  0.316 
27.58 
SD =  2.89 
15 1.2 2.364 
SD =  0.78 
28.52 
SD =  2.88 
4.5 2.946 
SD =  0.188 
27.12 
SD =  2.66 
 
 
The measured swelling force exhibited values only in the range 2-3 N, independently of pH 
and pressure, while the swelling time corresponding to the maximum swelling force was 25-
28 min. 
At the beginning of the process, fast swelling occurred, which was followed by slower 
swelling, but the force increased steadily. The curve could be fitted by the Korsmeyer–Peppas 
equation (r2 = 0.9930) (Fig. 16.) from 0 min up to approximately 25-28 min. In the period of 
formation of the gel barrier, there is strong physicochemical bonding between the polymer 
particles. After this period, further water molecules penetrate into the matrix and 
rearrangement of the bonding between the polymers occurs. Our experiments demonstrated 
that from this point the curve is basically linear (Fig. 16.). 
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Figure 16. Swelling curve of iota-carrageenan comprimate (compression force: 15 kN). 
 
The results demonstrated that the shapes of the swelling curves were independent of pH and 
the compression force. It may therefore be supposed that iota-carrageenan matrix tablets will 
behave similarly in the gastrointestinal tract as concerns the process of dissolution from 
sustained-release tablets. 
4.2.8 Conclusions 
 
It was concluded that the lactose content influences the physical parameters, the degree of 
dissolution and the profile of dissolution. When the proportion of lactose was smaller, the 
elasticity of the matrix was higher, which resulted in tablets with weak mechanical properties. 
Furthermore, the macromolecular particles could swell very well in the dissolution medium. 
The dissolution profiles could be fitted best with the Korsmeyer–Peppas model, but thanks to 
the lactose content the dissolution sometimes occurred in two phases. 
Application of a swelling force meter revealed the changes in the swelling force in matrix 
tablets. Two sections were observed in the swelling process: in the first, the degree of swelling 
and the swelling force were higher because of the strong bonds between the macromolecules, 
and this section could be fitted with the Korsmeyer–Peppas equation. In the second section, 
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the bonds became weaker and the rate of increase of the swelling force decreased. This test 
characterized very well the swelling process of the matrix system. 
 
 
 
5 FINAL CONCLUSIONS, NOVELTY, PRACTICAL 
USEFULNESS 
 
As described in the Introduction the aim was to develop modified release preparations 
containing riboflavin by different technological methods. Riboflavin was particularly suitable 
because it is absorbed to only a limited extent in the duodenum and jejunum as its passage 
through this region is rapid. The bioavailability of riboflavin may be increased by 
administration of a gastroretentive or modified release dosage form. 
 
The important novelty and practical usefulness of this work may be summarized as follows: 
 
- A new solid dosage form was developed through the layering of aqueous sodium 
riboflavin 5’-phosphate solution onto the surface of microcrystalline pellets (Cellet 
300 as core material), which were then filled into capsules. 
 
- The coating of the capsules was investigated and the influence of the thickness of 
the coating layer on the dissolution of sodium riboflavin 5’-phosphate was tested. 
The optimum film thickness was predicted with regard to the modified release of 
sodium riboflavin 5’-phosphate. 
 
- Monolithic matrix tablets containing sodium riboflavin 5’-phosphate were prepared 
by wet granulation according to a 32 full factorial design. A suitable MCC/lactose 
ratio and the best compression force were determined as concern an appropriate 
dissolution profile. 
 
- A new swelling force meter was developed for measurement of the swelling force 
in matrix tablets and characterization of the profile of the swelling curve. The 
swelling force meter was linked to a PC by an RS232 cable and the measured data 
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were evaluated with self-developed software. The monitor displayed the swelling 
force vs. time curve with the important parameters, which could be fitted with an 
Analysis menu. This equipment can be generally applied for matrix systems. 
 
The results and observations of the present study provide useful information for industrial 
technologists.  
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